AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29581669 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) applied for 10 sessions
Number of subjects: 60
Study 29581669 — intervention group
Group type: COMPARATOR
Intervention: Sham ESWT for 4 sessions
Number of subjects: 60
Study 27014804 — intervention group
Group type: EXPERIMENTAL
Intervention: Real PEMF
Number of subjects: 24
Study 27014804 — intervention group
Group type: COMPARATOR
Intervention: Sham PEMF
Number of subjects: 24
Study 26341262 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day use of infusion sets
Number of subjects: 24
Study 26341262 — intervention group
Group type: COMPARATOR
Intervention: 4-day use of infusion sets
Number of subjects: 24
Study 23656530 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) including estradiol alone or in combination with medroxyprogesterone acetate
Number of subjects: 150
Study 23656530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 20921909 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamic acid 1.5 grams daily orally in 3 divided doses during the 4-week induction with vincristine (1.5 mg/m² IV weekly)
Number of subjects: 94
Study 20921909 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral placebo 3 times daily)
Number of subjects: 94
Study 18083993 — intervention group
Group type: EXPERIMENTAL
Intervention: P + CI + CL
Number of subjects: 321
Study 12357041 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-type exercise training for 5 weeks
Number of subjects: 26
Study 12357041 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study 9793696 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine without aura (MwoA)
Number of subjects: 100
Study 9793696 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine with aura (MwA)
Number of subjects: 100
Study 9793696 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic tension-type headache (ETTH)
Number of subjects: 100
Study 9793696 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic tension-type headache (CTTH)
Number of subjects: 100
Study 9793696 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache-free subjects
Number of subjects: 100
Study 9793696 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall headache evolution
Number of subjects: 100
Study 7636936 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 70
Study 7636936 — intervention group
Group type: COMPARATOR
Intervention: Conventional antibiotic therapy
Number of subjects: 70
Study 2495916 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (60 mg orally for 4 weeks)
Number of subjects: 0
Study 2495916 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (60 mg orally)
Number of subjects: 0
Study 2495916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 921864 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral tilt during Caesarean section
Number of subjects: 60
Study 921864 — intervention group
Group type: COMPARATOR
Intervention: Right lateral tilt during Caesarean section
Number of subjects: 60
Study 30419981 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted lumbar puncture
Number of subjects: 40
Study 30419981 — intervention group
Group type: COMPARATOR
Intervention: Unassisted lumbar puncture
Number of subjects: 40
Study 28504358 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Family Therapy + Management As Usual (FFT + MAU)
Number of subjects: 111
Study 28504358 — intervention group
Group type: COMPARATOR
Intervention: Management As Usual (MAU)
Number of subjects: 111
Study 25597462 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional pure-tone audiometry (PTA)
Number of subjects: 30
Study 25597462 — intervention group
Group type: EXPERIMENTAL
Intervention: In-situ audiometry
Number of subjects: 30
Study 25597462 — intervention group
Group type: EXPERIMENTAL
Intervention: Resound devices
Number of subjects: 30
Study 25597462 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonak, Starkey, and Oticon devices
Number of subjects: 30
Study 24066729 — intervention group
Group type: EXPERIMENTAL
Intervention: 3Dr
Number of subjects: 156
Study 24066729 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D
Number of subjects: 156
Study 24066729 — intervention group
Group type: COMPARATOR
Intervention: 2D+
Number of subjects: 156
Study 21430252 — intervention group
Group type: EXPERIMENTAL
Intervention: FeSO4 plus ascorbic acid (AA)
Number of subjects: 16
Study 21430252 — intervention group
Group type: COMPARATOR
Intervention: NaFeEDTA
Number of subjects: 16
Study 19396409 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (twice daily)
Number of subjects: 47
Study 19396409 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 47
Study 17688458 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot FGAs
Number of subjects: 0
Study 17688458 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot SGAs
Number of subjects: 0
Study 15235364 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP with mastoid oscillation
Number of subjects: 84
Study 15235364 — intervention group
Group type: COMPARATOR
Intervention: CRP alone (nonoscillator group)
Number of subjects: 84
Study 11854763 — intervention group
Group type: EXPERIMENTAL
Intervention: Flotation-REST technique (experimental group)
Number of subjects: 37
Study 11854763 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 9645184 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine in a weight‐adapted dosage (75, 100 or 150 micrograms) plus 150 micrograms iodide
Number of subjects: 49
Study 9645184 — intervention group
Group type: COMPARATOR
Intervention: 100 micrograms levothyroxine plus 100 micrograms iodide
Number of subjects: 49
Study 7877292 — intervention group
Group type: EXPERIMENTAL
Intervention: Proband adults with moderate phonological disorder
Number of subjects: 52
Study 7877292 — intervention group
Group type: COMPARATOR
Intervention: Control adults with average articulation skills
Number of subjects: 52
Study 7877292 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 3064775 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy + tamoxifen (TAM), 30 mg daily for 1 year
Number of subjects: 3063
Study 3064775 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM alone
Number of subjects: 3063
Study 3064775 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM + CMF (CMF i.v. day 1 every 4 weeks x 9)
Number of subjects: 3063
Study 3064775 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy
Number of subjects: 3063
Study 31451364 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based PAINUCope intervention focused on barriers to pain management, pain, and analgesic adherence
Number of subjects: 228
Study 31451364 — intervention group
Group type: COMPARATOR
Intervention: Usual care (selection of games)
Number of subjects: 228
Study 31033909 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (L. reuteri)
Number of subjects: 100
Study 31033909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26123256 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 2.5 mg once daily for 26 weeks
Number of subjects: 93
Study 26123256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 23991896 — intervention group
Group type: EXPERIMENTAL
Intervention: subcutaneous immunotherapy with mixed depigmented‐polymerized birch and grass pollen extract
Number of subjects: 285
Study 23991896 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 285
Study 21692844 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 624
Study 19267255 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole treatment
Number of subjects: 0
Study 19267255 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 0
Study 17040583 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional neck dissection (FND)
Number of subjects: 21
Study 17040583 — intervention group
Group type: COMPARATOR
Intervention: Radical neck dissection (RND)
Number of subjects: 21
Study 15493172 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy performed for six cytology-positive patients (group I)
Number of subjects: 24
Study 15493172 — intervention group
Group type: EXPERIMENTAL
Intervention: No adjuvant therapy for six cytology-positive patients (group II)
Number of subjects: 24
Study 15493172 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy for twelve cytology-negative patients (control group)
Number of subjects: 24
Study 11550726 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased therapist self-disclosure during treatment
Number of subjects: 2
Study 11550726 — intervention group
Group type: COMPARATOR
Intervention: No therapist self-disclosure during treatment
Number of subjects: 2
Study 9590464 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 20 mg once daily
Number of subjects: 41
Study 9590464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 9590464 — intervention group
Group type: COMPARATOR
Intervention: Baclofen 10 mg once daily
Number of subjects: 41
Study 7930702 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral leishmaniasis (VL)
Number of subjects: 0
Study 7930702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutaneous leishmaniasis (CL)
Number of subjects: 0
Study 7930702 — intervention group
Group type: EXPERIMENTAL
Intervention: Both VL and CL
Number of subjects: 0
Study 2896128 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg
Number of subjects: 91
Study 2896128 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 91
Study 30601453 — intervention group
Group type: EXPERIMENTAL
Intervention: Most Bothersome Symptom Approach (MBSA)
Number of subjects: 31
Study 30601453 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrophy Symptoms Questionnaire (ASQ)
Number of subjects: 31
Study 30601453 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between MBSA and ASQ
Number of subjects: 31
Study 27281800 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g SR-l-arginine 3 times/d (4.5 g/d)
Number of subjects: 33
Study 27281800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 25716649 — intervention group
Group type: EXPERIMENTAL
Intervention: L50/H12.5/A5
Number of subjects: 327
Study 25716649 — intervention group
Group type: COMPARATOR
Intervention: L50+A5
Number of subjects: 327
Study 24260825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (100 mg and 200 mg every 12 hours for 3 days)
Number of subjects: 90
Study 24260825 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin (25 mg/kg/day for 2 weeks)
Number of subjects: 90
Study 24260825 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 90
Study 20374563 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous antiretroviral therapy (C-ART)
Number of subjects: 192
Study 20374563 — intervention group
Group type: COMPARATOR
Intervention: Interrupted antiretroviral therapy (2-months-off/4-months-on cycles [2/4-ART])
Number of subjects: 192
Study 17977618 — intervention group
Group type: EXPERIMENTAL
Intervention: Nibble-size snack in control condition
Number of subjects: 59
Study 17977618 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar-size snack in control condition
Number of subjects: 59
Study 17977618 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to consumption (chewing well)
Number of subjects: 59
Study 17977618 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no instruction to chew well)
Number of subjects: 59
Study 16873974 — intervention group
Group type: EXPERIMENTAL
Intervention: ipsilateral rTMS (IS group)
Number of subjects: 27
Study 16873974 — intervention group
Group type: EXPERIMENTAL
Intervention: contralateral rTMS (CS group)
Number of subjects: 27
Study 16873974 — intervention group
Group type: COMPARATOR
Intervention: sham rTMS (SS group)
Number of subjects: 27
Study 12891163 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological interventions (specific details not provided)
Number of subjects: 0
Study 10877493 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (5,000 IU retinyl palmitate and 30 mg beta-carotene daily, plus 200,000 IU retinyl palmitate at delivery)
Number of subjects: 312
Study 10877493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 8940670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir
Number of subjects: 0
Study 8940670 — intervention group
Group type: COMPARATOR
Intervention: Oral ganciclovir
Number of subjects: 0
Study 1549654 — intervention group
Group type: COMPARATOR
Intervention: High-osmolality contrast material
Number of subjects: 2113
Study 1549654 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-osmolality contrast material
Number of subjects: 2113
Study 3933067 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (20 mg)
Number of subjects: 0
Study 3933067 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepindolol (5 mg)
Number of subjects: 0
Study 3933067 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (20 mg)
Number of subjects: 0
Study 3933067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30865078 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher 30-day seizure frequency
Number of subjects: 120
Study 30865078 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower quality of life
Number of subjects: 120
Study 30865078 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid bipolar disorder
Number of subjects: 120
Study 30865078 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid panic disorder
Number of subjects: 120
Study 30865078 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid obsessive-compulsive disorder
Number of subjects: 120
Study 30055046 — intervention group
Group type: EXPERIMENTAL
Intervention: Samidorphan 10 mg/d
Number of subjects: 406
Study 30055046 — intervention group
Group type: EXPERIMENTAL
Intervention: Samidorphan 2.5 mg/d
Number of subjects: 406
Study 30055046 — intervention group
Group type: EXPERIMENTAL
Intervention: Samidorphan 1 mg/d
Number of subjects: 406
Study 30055046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 27091619 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy within 72 hours
Number of subjects: 64
Study 27091619 — intervention group
Group type: COMPARATOR
Intervention: Delayed cholecystectomy after 68 weeks
Number of subjects: 64
Study 25145456 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab treatment
Number of subjects: 84
Study 22702506 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001 (6 × 10(9) cfu/day)
Number of subjects: 425
Study 22702506 — intervention group
Group type: COMPARATOR
Intervention: Bifidobacterium animalis subsp lactis HN019 (9 × 10(9) cfu/day)
Number of subjects: 425
Study 20602089 — intervention group
Group type: EXPERIMENTAL
Intervention: D: ‐amphetamine (0.3 mg/kg, p.o.)
Number of subjects: 0
Study 20602089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18845497 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Gy whole-breast irradiation (WBI)
Number of subjects: 278
Study 18845497 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Gy whole-breast irradiation (WBI) plus 16 Gy tumour bed boost
Number of subjects: 278
Study 18845497 — intervention group
Group type: COMPARATOR
Intervention: Reoperation (reexcision plus radiotherapy or mastectomy alone)
Number of subjects: 278
Study 16093996 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oral rofecoxib
Number of subjects: 110
Study 16093996 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac (3 doses, 8-hourly)
Number of subjects: 110
Study 16093996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 14642554 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid (VIA) screening by nurses
Number of subjects: 78292
Study 14642554 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 78292
Study 14642554 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment received after diagnosis
Number of subjects: 78292
Study 11016665 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier creams (3 representative commercial barrier creams)
Number of subjects: 6
Study 11016665 — intervention group
Group type: COMPARATOR
Intervention: Control skin (no barrier cream used)
Number of subjects: 6
Study 8989723 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (20 mg/day orally in the evening)
Number of subjects: 30
Study 8989723 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study 1620139 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (0.02 mg/kg)
Number of subjects: 8
Study 1620139 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.04 mg/kg)
Number of subjects: 8
Study 1620139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6151914 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide 30 mg b.i.d. for 2 months
Number of subjects: 35
Study 6151914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 6151914 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide
Number of subjects: 35
Study 30661474 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/d sodium diet
Number of subjects: 17
Study 30661474 — intervention group
Group type: COMPARATOR
Intervention: 2300 mg/d sodium diet
Number of subjects: 17
Study 29278529 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 IU
Number of subjects: 44
Study 29278529 — intervention group
Group type: COMPARATOR
Intervention: 1 mL sodium chloride 0.9 (placebo)
Number of subjects: 44
Study 27270263 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐thyroxine replacement therapy
Number of subjects: 378
Study 27270263 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 378
Study 24610399 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) and quitline referral (Group MNQ)
Number of subjects: 157
Study 24610399 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) and quitline referral (Group UNQ)
Number of subjects: 157
Study 24610399 — intervention group
Group type: COMPARATOR
Intervention: Quitline referral only (Group UQ)
Number of subjects: 157
Study 22270321 — intervention group
Group type: EXPERIMENTAL
Intervention: S-warfarin (25 mg single oral dose)
Number of subjects: 19
Study 22270321 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal PK sampling schedule
Number of subjects: 19
Study 22270321 — intervention group
Group type: EXPERIMENTAL
Intervention: Selected PK sampling time points
Number of subjects: 19
Study 19811890 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination therapy (CTh)
Number of subjects: 68
Study 19811890 — intervention group
Group type: COMPARATOR
Intervention: Conventional voice therapy
Number of subjects: 68
Study 17918147 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA)
Number of subjects: 48
Study 17918147 — intervention group
Group type: COMPARATOR
Intervention: Systemic heparin anticoagulation
Number of subjects: 48
Study 16239862 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 36
Study 16239862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 11543743 — intervention group
Group type: EXPERIMENTAL
Intervention: Galanthamine (cholinergic REM induction test, CRIT)
Number of subjects: 40
Study 11543743 — intervention group
Group type: COMPARATOR
Intervention: Baseline conditions (alcohol-dependent patients)
Number of subjects: 40
Study 11543743 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who remained abstinent (n=11)
Number of subjects: 40
Study 11543743 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (age- and gender-matched)
Number of subjects: 40
Study 9603127 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (inhNO)
Number of subjects: 30
Study 9603127 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 30
Study 7995617 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous plus pulsatile overnight GH administration (50% constant delivery + 3 pulses)
Number of subjects: 10
Study 7995617 — intervention group
Group type: COMPARATOR
Intervention: Single daily injection of GH
Number of subjects: 10
Study 3593904 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (oral doses)
Number of subjects: 15
Study 29797217 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care management
Number of subjects: 1178
Study 29797217 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 1178
Study 27359223 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on EVT
Number of subjects: 264
Study 27359223 — intervention group
Group type: COMPARATOR
Intervention: IV tPA alone
Number of subjects: 264
Study 24931747 — intervention group
Group type: EXPERIMENTAL
Intervention: China rubra 7CH plus quinine
Number of subjects: 211
Study 24931747 — intervention group
Group type: COMPARATOR
Intervention: Quinine only (Standard group)
Number of subjects: 211
Study 24113040 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan and amlodipine taken in the morning
Number of subjects: 108
Study 24113040 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan and amlodipine taken at bedtime
Number of subjects: 108
Study 24113040 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan in the morning and amlodipine at bedtime
Number of subjects: 108
Study 24113040 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine in the morning and telmisartan at bedtime
Number of subjects: 108
Study 21462101 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer training 3 times per week, average 25 min at 0.6 watt/kg
Number of subjects: 23
Study 21462101 — intervention group
Group type: COMPARATOR
Intervention: Control group without sports therapy
Number of subjects: 23